Pfizer and Merck & Co announced a clinical trial biotech partnering deal to test Merck’s Investigational Anti-PD-1 Antibody Pembrolizumab and Pfizer’s Crizotinib (XALKORI) in combination for patients with ALK-positive advanced or metastatic non-small cell lung cancer.
The Phase Ib trial will be initiated.
Pfizer’s XALKORI is a kinase inhibitor indicated for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test.
Merck describes Pembrolizumab (MK-3475) as “an investigational, humanized, monoclonal antibody against PD-1 designed to reactivate anti-tumor immunity.” The company estimates that by the end of 2014, the pembrolizumab development program will include more than 24 clinical trials involving an estimated 6,000 patients in nearly 300 locations worldwide.
For further deal information visit Current Agreements (subscription required)
Report: Partnering Agreements with Pfizer 2009-2014
Report: Partnering Agreements with Merck & Co. 2009-2014
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity